News

China Shenghuo Pharmaceutical is a specialty pharmaceutical company that focuses on the manufacture, research, development and marketing of Sanchi-based medicinal and pharmaceutical, nutritional supplement and cosmetic products. China

ICON said that with this alliance it is strengthening its current biomarker solution to include an integrated suite of labeling, separation and mass spectrometry technologies for protein and

Dalton supplies chemistry, analytical and formulation development services to the biotechnology and pharmaceutical industries in the areas of chemistry, medicinal chemistry and fine chemical manufacture. The company provides

Pozen is expected to receive the milestone as a result of the grant of marketing and pricing approval for Vimovo (naproxen/ esomeprazole magnesium) 500/20mg modified-release tablets in the

arYla is expected to be used to optimise a range of properties critical to the successful development of a therapeutic or diagnostic antibody. The arYla technology results from

BOL-303259-X has been developed for the potential treatment of glaucoma and ocular hypertension and was licensed to Bausch + Lomb by NicOx in March 2010. BOL-303259-X Phase 2b

Pfizer said that the Emphasis-HF trial demonstrated a 37% relative risk reduction for the eplerenone group compared to placebo in the primary composite endpoint of death from CV

Earlier this year, Menicon obtained exclusive distribution rights for Optimed’s products in Japan and Taiwan. Optimed said that CAPTIV8 is a web-based 3D animation software that can be

CytomX CEO Nancy Stagliano said that following closely on the recent Series B financing, they believe these grants are another validation of the potential of their site-directed antibody